Bjartell, "Tumor markers in prostate cancer I: blood-based markers," Acta Oncologica, vol. 50, supplement 1, pp. 61-75, 2011.Shariat SF, Semjonow A, Lilja H, Savage C, Vickers AJ, Bjartell A. Tumor markers in prostate cancer I: blood-based markers. Acta Oncol. 2011; 50 Suppl ...
CAFs may derive from various origins (e.g. myofibroblasts, epithelial and mesenchymal cells) and they are heterogeneous in their phenotypes and functions [10,11]. These activated, specialized forms of fibroblasts can be identified through positive expression of markers such as alpha-smooth muscle ...
The aim of this study was to identify metabolic markers in serum and plasma samples from PCa patients and controls with benign prostatic hyperplasia (BPH) using different suitable methodology platforms, including nuclear magnetic resonance spectroscopy (MRS), mass spectrometry (MS) and gas chromatography...
Many genetic cancer markers involve a point mutation on a particular gene. Point mutations are difficult to detect because they are in such small quantities in blood compared to normal cell-freenucleic acids, or wild type. One way that scientists have made PCR more sensitive is by using genetic...
It is imperative to study the role of these mechanisms in prospective clinical trials in a quest to find predictive markers that can help to tailor treatments, keeping in view the molecular heterogeneity. 展开 关键词: Keywords bladder cancer marker molecular biology prediction ...
Use of molecular markers in urine, tissue or blood offers potential opportunities to improve understanding of bladder cancer biology which may help identif
Results: Significant correlations were found between CEA and blood Cd concentrations or between CEA and period of work under exposure. Multiple regression tests revealed also relationships between some cancer markers and the work period, and thereby the lifetime exposure to heavy metals. Duration of ...
In comparison, an existing blood test called CancerSEEK that looks for genetic and protein tumour markers in the blood was found to detect70 per centof common cancers on average. However, CancerSEEK was tested on earlier-stage cancers which probably made detection harder, says Mouliere. ...
Variations in their levels in tissues or blood may indicate the development of diseases such as cancer. Protein markers can be detected in tissue biopsy sections analyzed by immunohistochemistry (IHC) upon diagnostic nota- bly to determine cancer molecular subtype. For instance, breast tumor tissues ...
Peripheral blood biomarkers would be most convenient to predict treatment outcome and immune-related adverse events (irAEs) in candidate patients. This study explored associations between inflammation-related peripheral blood markers and onset of irAEs and outcome in patients with advanced NSCLC receiving...